Showing 4421-4430 of 5557 results for "".
- Long-term Outcomes Impaired by Cutaneous Chronic Graft-vs-Host Diseasehttps://practicaldermatology.com/news/improved-melanoma-prognosis-with-31-gep/2462255/New analysis results indicate that cutaneous chronic graft-vs-host disease (GVHD) was linked with impaired long-term patient-reported outcomes (PROs). Researchers for the 9-center study conducted by the Chronic GVHD Consortium examined the association between different ty
- Analysis: Mix of Low- and Fair-quality Information for Hidradenitis Suppurativa Treatments on TikTokhttps://practicaldermatology.com/news/complementary-and-alternative-medicine-for-hidradenitis-suppurativa-discussed-on-tiktok-a-cross-sectional-analysis/2462251/Patients getting information on Hidradenitis suppurativa (HS) from TikTok were frequently exposed to low-quality information, a new study suggests. "Hidradenitis suppurativa (HS) is a painful, chronic inflammatory skin disease that negatively impacts quality of life," the
- CD19 CAR T-Cell Transfer Therapy Shows Promise for Systemic Lupus Erythematosushttps://practicaldermatology.com/news/cd19-car-t-cell-transfer-therapy-and-systemic-lupus-erythematosus/2462248/Results from a recent analysis in the New England Journal of Medicine suggested a potentially effective approach for treating autoimmune diseases like systemic lupus erythematosus (SLE), idiopathic inflammatory myositis, and systemic sclerosis. The case series analysi
- Intravenous Ertapenem Shows Improvement in Hidradenitis Suppurativahttps://practicaldermatology.com/news/intravenous-ertapenem-for-hidradenitis-suppurativa-efficacy-and-patient-satisfaction/2462245/Results from a new analysis indicated that intravenous ertapenem was associated with improvements in markers of hidradenitis suppurativa (HS) and was linked with increased patient satisfaction. The retrospective analysis included medical records of 98 patients with HS who
- FDA Approves First Medication to Treat Severe Frostbitehttps://practicaldermatology.com/news/fda-approves-first-medication-to-treat-severe-frostbite/2462244/The FDA has approved Eicos Sciences' Aurlumyn (iloprost) injection to treat severe frostbite in adults to reduce the risk of finger or toe amputation. “This approval provides patients with the first-ever treatment option for severe frostbite,” Norman Stockbridge, MD, PhD
- Galderma Announces Filing Acceptance for Investigational Prurigo Nodularis and AD Treatmenthttps://practicaldermatology.com/news/galderma-announces-filing-recepetion-for-investigational-prurigo-nodularis-treatment/2462243/Galderma announced the acceptance of its Biologics License Applications for nemolizumab, a first-in-class monoclonal antibody IL-31 inhibitor, for the treatment of prurigo nodularis in adults and adolescents with moderate-to-severe atopic dermatitis (AD). The agency, according to a news
- Cutera Announces International Commercial Launch of AviClear for the Treatment of Acnehttps://practicaldermatology.com/news/cutera-announces-international-commercial-launch-of-aviclear-for-the-treatment-of-acne/2462240/Cutera announced the international limited commercial release of AviClear, which the company describes as the first energy-based device FDA-cleared for the long-term treatment of mild, moderate, and severe acne. AviClear is now commercially available, on a limited basis, in the UK, Europe, a
- DISCREET: Apremilast Effective for Genital Psoriasis for Treatment Nonrespondershttps://practicaldermatology.com/news/discreet/2462239/Apremilast was efficacious in reducing the symptoms of genital psoriasis (G-PsO) in patients who didn't respond to topical treatments or who were not adequately controlled by topical therapy, new research indicates. DISCREET aimed to evaluate the efficacy and safety of apremil
- Biofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluzhttps://practicaldermatology.com/news/biofrontera-inc-announces-fda-filing-of-supplemental-new-drug-application-for-ameluz/2462237/Biofrontera Inc., a biopharmaceutical company specializing in the commercialization of dermatologic products, today announced that the U.S. Food and Drug Administration (FDA) has issued a "no filing review issues identified" letter regarding the sNDA (supplementary New Drug Application) submitted
- Analysis: Inconsistent Pretreatment Testing for Inflammatory Skin Diseaseshttps://practicaldermatology.com/news/analysis-inconsistent-pretreatment-testing-for-inflammatory-skin-diseases/2462233/A new analysis of US commercial insurance claims databases indicated that less than 60% of people living with chronic inflammatory skin diseases (CISD) receive recommended pretreatment testing.